Follow
Florian Handle
Florian Handle
Institute of Pathology, Neuropathology & Molecular Pathology, Medical University of Innsbruck
Verified email at i-med.ac.at
Title
Cited by
Cited by
Year
The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy
M Puhr, J Hoefer, A Eigentler, C Ploner, F Handle, G Schaefer, J Kroon, ...
Clinical Cancer Research 24 (4), 927-938, 2018
1642018
The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling
G Nappo, F Handle, FR Santer, RV McNeill, RI Seed, AT Collins, ...
Oncogenesis 6 (5), e342-e342, 2017
952017
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao, F Handle, A Erickson, S Prekovic, ...
Nature communications 12 (1), 5307, 2021
752021
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
J Hoefer, M Akbor, F Handle, P Ofer, M Puhr, W Parson, Z Culig, ...
Oncotarget 7 (37), 59781, 2016
642016
IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9
HHH Erb, RV Langlechner, PL Moser, F Handle, T Casneuf, K Verstraeten, ...
Endocrine-related cancer 20 (5), 677, 2013
642013
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
F Handle, S Prekovic, C Helsen, T Van den Broeck, E Smeets, L Moris, ...
Scientific reports 9 (1), 13786, 2019
572019
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer
M Puhr, J Hoefer, A Eigentler, D Dietrich, G Van Leenders, B Uhl, ...
Oncogene 35 (18), 2322-2332, 2016
492016
SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells
F Handle, HHH Erb, B Luef, J Hoefer, D Dietrich, W Parson, G Kristiansen, ...
Molecular Cancer Research 14 (6), 574-585, 2016
452016
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
F Handle, M Puhr, G Schaefer, N Lorito, J Hoefer, M Gruber, ...
Molecular cancer therapeutics 17 (12), 2722-2731, 2018
382018
Molecular underpinnings of enzalutamide resistance
S Prekovic, T Van den Broeck, S Linder, ME van Royen, AB Houtsmuller, ...
Endocrine-related cancer 25 (11), R545-R557, 2018
342018
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy
FR Santer, HHH Erb, SJ Oh, F Handle, GE Feiersinger, B Luef, H Bu, ...
Oncotarget 6 (8), 6105, 2015
342015
The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells
M Gruber, F Handle, Z Culig
The Prostate 80 (3), 267-273, 2020
302020
On the use of frequency-domain reconstruction algorithms for photoacoustic imaging
R Schulze, G Zangerl, M Holotta, D Meyer, F Handle, R Nuster, G Paltauf, ...
Journal of biomedical optics 16 (8), 086002-086002-6, 2011
292011
The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1
B Luef, F Handle, G Kharaishvili, M Hager, J Rainer, G Janetschek, ...
Endocrine-Related Cancer 23 (6), 495-508, 2016
262016
The androgen receptor depends on ligand‐binding domain dimerization for transcriptional activation
S El Kharraz, V Dubois, ME van Royen, AB Houtsmuller, E Pavlova, ...
EMBO reports 22 (12), e52764, 2021
252021
Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo-and anti-androgen therapy in advanced prostate cancer
M Puhr, A Eigentler, F Handle, H Hackl, C Ploner, I Heidegger, ...
Oncogene 40 (17), 3087-3100, 2021
212021
Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
HHH Erb, J Bodenbender, F Handle, T Diehl, L Donix, I Tsaur, M Gleave, ...
PLoS One 15 (8), e0237248, 2020
212020
p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer
M Gruber, L Ferrone, M Puhr, FR Santer, T Furlan, IE Eder, N Sampson, ...
Endocrine-Related Cancer 27 (3), 187-198, 2020
202020
MYC-mediated ribosomal gene expression sensitizes enzalutamide-resistant prostate cancer cells to EP300/CREBBP inhibitors
T Furlan, A Kirchmair, N Sampson, M Puhr, M Gruber, Z Trajanoski, ...
The American Journal of Pathology 191 (6), 1094-1107, 2021
182021
Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits
E Demetz, I Tancevski, K Duwensee, U Stanzl, E Huber, C Heim, ...
Atherosclerosis 222 (2), 360-366, 2012
162012
The system can't perform the operation now. Try again later.
Articles 1–20